trending Market Intelligence /marketintelligence/en/news-insights/trending/3VoEqvJwrorUGg-QZY3O5Q2 content esgSubNav
In This List

Summa Equity buys majority stake in Olink Proteomics

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Podcast

Street Talk | Episode 98: Regulatory scrutiny having cooling effect on community bank M&A

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022


Summa Equity buys majority stake in Olink Proteomics

Summa Equity purchased Sweden-headquartered life sciences company Olink Proteomics AB, which has developed technology for human biomarker discovery.

Under the deal, the private equity firm will become the company's majority shareholder, while its founder Ulf Landegren and the management team will continue as stockholders.

Moelis & Co. LLC served as financial adviser to Summa, White & Case was its legal adviser, LEK Consulting was its commercial adviser and KPMG was its accounting adviser. J.P. Morgan Securities LLC acted as financial adviser to Olink, while Wiggin, Dana LLP and Lindahl were its legal advisers.